Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-177: Pembrolizumab vs Chemotherapy in MSI-H/dMMR Colorectal Cancer
NCT02563002Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in colorectal carcinoma (CRC) comparing Pembrolizumab with Standard of Care (2 arms). Primary endpoints: Progression-Free Survival up to 59 months and Overall Survival up to 59 months. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT02563002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563002.